[Table_Author] 分析师：王俐媛 执业证书号：S1030524080001 电话：0755-83199599 邮箱：wangly1@csco.com.cn 研究助理：徐伊琳 电话：0755-23602217 邮箱：xuyl@csco.com.cn [Table_Industry] [Table_BaseData] 1) 区间回顾。2 月 9 日-2 月 27 日，医药生物板块跌 0.32%，跑输 Wind 全 A（3.89%）和沪深 300（1.44%）。 从细分板块来看，医疗耗材（3.64%）、其他生物制品 （2.78%）和原料药（0.68%）领涨，线下药店（-2.12%）、 化学制剂（-1.53%）和医药流通（-1.37%）领跌。从个 股来看，万泽股份（44.06%）、科源制药（34.82%）和 多瑞医药（20.77%）涨幅居前，国发股份（-10.19%）、 泽璟制药-U（-10.18%）和花园生物（-9.4%）跌幅居 前。 2) 测序仪龙头押注技术跃迁。2 月 23 日，华大智造公告 与瑞士 Swiss Rockets 达成战略交易，以 5000 万美元 对价出售美国子公司 CGI 股权并锁 ...

Core Viewpoint - BGI Genomics (688114) plans to acquire 100% equity of two companies, Shenzhen BGI Sanjian Qifa Technology Co., Ltd. and Hangzhou BGI Xufeng Technology Co., Ltd., for a total of 366 million yuan, integrating cutting-edge technologies in spatial omics and nanopore sequencing into its business [1][3]. Group 1: Acquisition Details - The total acquisition price is 366 million yuan, with BGI Sanjian Qifa valued at 158 million yuan and BGI Xufeng at 208 million yuan [3]. - BGI Genomics will also inject 70 million yuan and 60 million yuan into BGI Sanjian Qifa and BGI Xufeng, respectively, to support their operations and business expansion [3][4]. - A loan of 70 million yuan will be provided to BGI Xufeng at an interest rate of 2.5% for three years to repay debts [3]. Group 2: Financial Performance - Both target companies are currently in a high-investment R&D phase and have not yet achieved profitability. BGI Sanjian Qifa reported revenues of 60.74 million yuan and 27.99 million yuan for 2024 and January-October 2025, respectively, with net losses of 11.71 million yuan and 44.98 million yuan [5]. - BGI Xufeng's revenues were 44.02 million yuan and 66.14 million yuan for the same periods, with net losses of 70.66 million yuan and 85.01 million yuan [5]. Group 3: Strategic Implications - The acquisition will enable BGI Genomics to create a comprehensive technology chain covering short-read, long-read, and spatial omics technologies, positioning it uniquely in the global market [5][6]. - The integration of these technologies is expected to enhance the company's competitive edge and profitability in the long term, with BGI Xufeng and BGI Sanjian Qifa projected to achieve profitability by 2026 and 2028, respectively [6][7]. Group 4: Valuation and Market Reaction - The valuation of BGI Sanjian Qifa shows a high appreciation rate of 2460.66%, while BGI Xufeng has a valuation increase of 296.55% [8]. - The acquisition pricing is considered reasonable compared to industry standards, with dynamic price-to-sales ratios around 3 times, significantly lower than comparable companies in their respective fields [9]. Group 5: Performance Commitments - Performance commitments have been established, with BGI Sanjian Qifa expected to achieve net profits of no less than 5 million yuan, 18.7 million yuan, and 26.4 million yuan from 2026 to 2028, totaling at least 50.1 million yuan [9]. - BGI Xufeng is expected to achieve net profits of no less than 5.2 million yuan, 24.6 million yuan, and 53 million yuan from 2028 to 2030, totaling at least 82.8 million yuan [9].

Core Viewpoint - BGI Genomics is making a significant move by acquiring 100% equity of two subsidiaries, Shenzhen Huada Sanjian Qifa Technology Co., Ltd. and Hangzhou Huada Xufeng Technology Co., Ltd., for a total of 366 million yuan, integrating cutting-edge technologies in spatial omics and nanopore sequencing into its operations [1][3]. Group 1: Acquisition Details - The total acquisition price is 366 million yuan, with Shenzhen Huada Sanjian Qifa valued at 158 million yuan and Hangzhou Huada Xufeng at 208 million yuan [3]. - BGI Genomics plans to inject 70 million yuan and 60 million yuan into the respective companies for operational expansion and working capital [3]. - A loan of 70 million yuan will be provided to Hangzhou Huada Xufeng at a 2.5% interest rate for three years to repay existing debts [3]. Group 2: Financial Performance - Both acquired companies are currently in a high-investment R&D phase and have not yet achieved profitability, with significant losses reported [5][7]. - Financial data shows that Shenzhen Huada Sanjian Qifa had revenues of 60.74 million yuan and 27.99 million yuan for 2024 and the first ten months of 2025, respectively, with net losses of 11.71 million yuan and 44.98 million yuan [7]. - Hangzhou Huada Xufeng reported revenues of 44.02 million yuan and 66.14 million yuan for the same periods, with net losses of 70.66 million yuan and 85.01 million yuan [7]. Group 3: Strategic Implications - The acquisition aims to create a comprehensive technology chain that includes short-read, long-read, and spatial omics technologies, positioning BGI Genomics as a unique player in the global market [6][8]. - The integration of these technologies is expected to enhance customer service capabilities and meet diverse research needs [8]. - The companies are projected to achieve profitability by 2026 and 2028, respectively, with specific profit commitments outlined [10]. Group 4: Valuation and Market Perception - The valuation of the acquired companies shows a high appreciation rate, with Shenzhen Huada Sanjian Qifa at 2460.66% and Hangzhou Huada Xufeng at 296.55% [9]. - The rationale behind the high valuation is attributed to the companies' technological advantages and potential strategic value in the market [9]. - The acquisition is viewed as a cost-effective move for BGI Genomics, aligning with industry standards and providing a competitive edge [9].

Core Viewpoint - BGI Genomics (688114) plans to acquire 100% equity of two companies, Shenzhen BGI Sanjian Qifa Technology Co., Ltd. and Hangzhou BGI Xufeng Technology Co., Ltd., for a total of 366 million yuan, integrating cutting-edge technologies in spatial omics and nanopore sequencing into its business [2][4]. Group 1: Acquisition Details - The total transaction price for the acquisition is 366 million yuan, with BGI Sanjian Qifa valued at 158 million yuan and BGI Xufeng at 208 million yuan [4]. - BGI Genomics will also inject 70 million yuan and 60 million yuan into BGI Sanjian Qifa and BGI Xufeng, respectively, to support their operations and business expansion [4]. - A loan of 70 million yuan will be provided to BGI Xufeng at an interest rate of 2.5% for three years to repay debts [4]. Group 2: Financial Performance and Projections - Both BGI Sanjian Qifa and BGI Xufeng are currently in the R&D phase and have not yet achieved profitability, with projected revenues of 607.43 million yuan and 279.96 million yuan for BGI Sanjian Qifa in 2024 and 2025, respectively [6]. - BGI Xufeng is expected to generate revenues of 440.23 million yuan and 661.38 million yuan in the same periods, with significant net losses reported [6]. - Profitability is anticipated for BGI Sanjian Qifa and BGI Xufeng by 2026 and 2028, respectively, with performance commitments set for net profits during these years [7][11]. Group 3: Strategic Implications - The acquisition will enable BGI Genomics to create a comprehensive technology chain covering short-read, long-read, and spatial omics technologies, positioning it uniquely in the global market [6][8]. - The integration of these technologies is expected to enhance BGI Genomics' competitive edge and profitability in the long term, potentially serving as a new growth engine [7][8]. - The strategic alignment of BGI Sanjian Qifa's spatial omics with BGI Genomics' existing platforms is anticipated to attract new customers and meet complex research needs [8]. Group 4: Valuation and Market Considerations - The valuation of BGI Sanjian Qifa shows a high appreciation rate of 2460.66%, while BGI Xufeng has a valuation increase of 296.55% [9][10]. - The assessment of these companies considers not only tangible assets but also intangible resources such as brand, technology, and customer relationships [10]. - The transaction is viewed as having a strong cost advantage compared to industry peers, with dynamic price-to-sales ratios around 3 times lower than comparable companies in their respective fields [10].

Hot Topics - Jia Mei Packaging's stock trading suspension review has concluded, and the stock will resume trading tomorrow [1] - Fenglong Co., Ltd.'s stock trading suspension review has concluded, and the stock will resume trading tomorrow [2] - Hongbaoli does not produce epoxy propylene products, and its subsidiary's related project has entered the preliminary preparation stage for trial production [2] - Hunan Gold's future market price for gold products has uncertainty regarding whether it can continue to rise or maintain high levels [2] - Tongding Interconnection's current operating conditions are normal, with no significant changes in the internal and external operating environment [3] - Tiandi Online's recent operating conditions and internal and external operating environment show no significant changes [4] - Dayue City reports no significant changes in its recent operating conditions and internal and external environment [5] - Huangtai Liquor Industry is not involved in hot concept matters, and its current operating conditions are normal [6] Performance - Leshan Electric Power reported a net profit of 23.4023 million yuan for 2025, an increase of 3.68% year-on-year [7] - Great Wall Motors sold 90,300 vehicles in January, a year-on-year increase of 11.59% [8] - Seres sold 45,900 vehicles in January, a year-on-year increase of 104.85% [9] - GAC Group sold 116,600 vehicles in January, a year-on-year increase of 18.47% [10] - BAIC Blue Valley's subsidiary sold 8,073 vehicles in January, a year-on-year increase of 11.83% [11] Shareholding Changes - Chipone Technology's shareholders plan to reduce their holdings by no more than 1.95% of the company's shares [30] Share Buybacks - Chuzhou Dongfeng's controlling shareholder proposed to repurchase shares worth 50 million to 100 million yuan [31] - GoerTek has increased the total amount for share repurchase from no less than 500 million yuan (inclusive) and no more than 1 billion yuan (inclusive) to no less than 1 billion yuan (inclusive) and no more than 1.5 billion yuan (inclusive) [31] Contract Awards - Jerry Holdings' wholly-owned subsidiary signed a sales contract for gas turbine generator sets worth approximately 1.265 billion yuan with a U.S. client [32] - Fulongma is expected to win four sanitation service projects in January, with a total first-year service fee of 83.5364 million yuan [34] Equity Changes - Yanzhou Coal Mining is transferring 100% equity of Xintai Coal [33] Mergers and Acquisitions - BGI Genomics plans to acquire 100% equity of Sanjian Qifa and 100% equity of BGI Xufeng to integrate two cutting-edge technology platforms in spatial omics and nanopore sequencing [34] Refinancing - Sanjia Technology (rights protection) plans to issue shares to its controlling shareholder to raise no more than 300 million yuan for working capital and repaying bank loans [35] Other - Fushikong's actual controller, chairman, and general manager Chen Yongliang has been placed under detention [36] - China Mobile's VAT tax category adjustment will change the applicable VAT rate from 6% to 9% [37] - China Telecom's VAT tax category adjustment will impact the company's revenue and profits [38] - China Unicom's VAT tax category adjustment will change the applicable VAT rate from 6% to 9% [39] - Nanwang Energy's price policy adjustment for pumped storage and new energy storage will increase uncertainty in revenue and profits from pumped storage power stations [39] - Wanbangde has completed the enrollment of 100 subjects for the clinical trials of Shishan Jianjia controlled-release tablets phases II and III [39] - Penghui Energy has submitted an application for issuing H-shares and listing on the Hong Kong Stock Exchange [40] - Haichuang Pharmaceutical has passed the GMP compliance inspection for drugs [41]

Core Viewpoint - The article discusses the breakthrough of a new spatial transcriptomics technology, Stereo-seq V2, developed by a Chinese research team, which enables high-resolution, in-situ analysis of host-microbe interactions in FFPE samples, unlocking vast clinical data for research and diagnostics [3][4]. Breakthroughs - Breakthrough 1: Unlocking 90% of Clinical "Treasures" - Over 90% of clinical samples are FFPE, which have been difficult to analyze due to RNA degradation. Stereo-seq V2 can analyze samples preserved for up to 9 years, providing detailed spatial maps of tumor gene expression [8][9]. - Breakthrough 2: Random Primers as a "Universal Key" - Unlike traditional methods that only capture mRNA, Stereo-seq V2 uses random primers to capture the entire transcriptome, significantly increasing the number of detected genes and allowing for precise identification of tumor-specific splicing events [10][11]. - Breakthrough 3: In-situ Capture of Pathogens and Immune Cells - Stereo-seq V2 allows for simultaneous capture of all human and microbial RNA, enabling comprehensive analysis of host-microbe interactions without prior knowledge of the pathogen [12][13]. - Breakthrough 4: Wide Clinical Applications - The technology has broad implications for precision medicine, including identifying gene copy number variations in breast cancer and tracking the dynamics of immune responses in tuberculosis infections [16][19]. Implications for Research and Development - The advancements in Stereo-seq V2 position it as a powerful tool for various fields, including infectious diseases, antibody drug development, and neuroscience, facilitating high-resolution spatial analysis of precious archived samples [25]. - The technology represents a significant leap from merely observing cells to understanding the intricate interactions within them, marking a new era in life sciences research [20][21].

Investment Rating - The report maintains an "Accumulate" rating for the company, indicating an expected relative performance increase of 5% to 15% over the next 6 to 12 months compared to the benchmark index [2][9]. Core Views - The company has shown resilience in performance amidst geopolitical risks, with steady growth in global sequencing installations. The core sequencing business is experiencing robust growth, supported by domestic market recovery and accelerated overseas expansion [2][6]. - The company achieved a revenue of 3.01 billion yuan in 2024, reflecting a year-on-year growth of 3.48%. However, the net profit attributable to the parent company was -601 million yuan, a slight improvement of 1.10% year-on-year [3][6]. - The report highlights the company's competitive advantage as a domestic leader in sequencing instruments, with a global market share of approximately 7.1% based on revenue and 28.2% based on new installations [6]. Summary by Sections Financial Performance - The company forecasts revenues of 3.61 billion yuan for 2025, with a growth rate of 20%. The net profit is expected to improve significantly, reaching -177 million yuan, a 70% year-on-year increase [2][7]. - In Q1 2025, the company reported a revenue of 455 million yuan, a decline of 14.26% year-on-year, while the net profit attributable to the parent company was -133 million yuan, an increase of 33.67% year-on-year [3][6]. Market Position - The company has accelerated its global expansion, with nearly 900 overseas marketing personnel and a significant increase in installed sequencing machines, totaling over 4,500 units globally by the end of 2024 [6]. - The domestic market share for newly installed instruments reached approximately 63.8%, with revenue market share increasing to 39% [6]. Cost and Efficiency - The report notes a decrease in sales expense ratio to 25.42% and a slight increase in management expense ratio to 19.98%. The R&D expense ratio decreased to 24.77%, indicating improved operational efficiency [6]. - The gross margin for 2024 was reported at 55.51%, a decrease of 3.96 percentage points year-on-year, primarily due to changes in product mix [6]. Future Outlook - The company is expected to continue benefiting from innovative products and global channel development, with projected revenues of 4.5 billion yuan in 2026 and 5.6 billion yuan in 2027, reflecting a growth rate of 25% and 24% respectively [2][6]. - The net profit is anticipated to turn positive by 2026, reaching 182 million yuan by 2027, indicating a significant turnaround from previous losses [2][6].